Core Viewpoint - The visit of Yantai Municipal Party Secretary Jiang Cheng to Yantai Progi Pharmaceutical Technology Co., Ltd. highlights the importance of the biopharmaceutical industry as a strategic emerging industry in Yantai, emphasizing the need for technological innovation, product development, and talent cultivation to enhance industry competitiveness [1][2]. Company Overview - Yantai Progi Pharmaceutical Technology Co., Ltd. is an innovative high-tech private enterprise established in April 2015, located in the Yantai Huangbohai New Area, and is a wholly-owned subsidiary of Beijing Progi Biotechnology Development Co., Ltd. [2][3] - The company has built the first phase of the Yantai Progi Biopharmaceutical Park, covering 200 acres with a construction area of 120,000 square meters, and has completed the main construction of 12 buildings including production workshops and quality inspection buildings [2]. - Progi specializes in the development and production of recombinant protein drugs, antibody drugs, and in vitro diagnostic reagents, with experience in successfully developing national Class 1 new drugs and Class 3 medical devices [2][3]. Industry Context - The biopharmaceutical industry is a key focus for Yantai's development, with the city establishing a systematic layout of "1+3+X" for the industry, promoting various development zones and clusters [4][5]. - As of June this year, Yantai has 274 key enterprises in the biopharmaceutical and health industry, including 146 above-scale enterprises, featuring leading companies such as Rongchang Bio and Green Leaf Pharmaceutical [5][6]. - The rapid development of Yantai's biopharmaceutical industry is attributed to the "chain leader system," which focuses on building, extending, and strengthening industrial chains, with biopharmaceuticals being a model industry for this initiative [5][6].